Search

Germany: Continuous Tableting Line GEA Wins CPhI Pharma Award for Equipment Excellence

| Editor: Alexander Stark

GEA was awarded for best manufacturing technology and equipment at the CPhI Pharma Awards, which took place during the trade fair CPhI Worldwide in Barcelona, Spain.

Related Companies

GEA’s ConsiGma continuous processing platform was presented with the award for manufacturing technology and equipment during the CPhI Awards ceremony this week. From left to right: Riccardo Tomassetti, Dr. Marcus Michel, Phil Gabb, Mark Rowland, Bernat Rodriguez.
GEA’s ConsiGma continuous processing platform was presented with the award for manufacturing technology and equipment during the CPhI Awards ceremony this week. From left to right: Riccardo Tomassetti, Dr. Marcus Michel, Phil Gabb, Mark Rowland, Bernat Rodriguez.
(Source: GEA Group)

Düsseldorf/Germany — GEA won the Award “Excellence in Pharma: Manufacturing Technology and Equipment” for their ConsiGma continuous processing platform. This continuous tableting line is a multipurpose platform that has been designed to transfer powder into coated tablets in development, pilot, clinical and production facilities in a single compact unit. The system can perform dosing and mixing of raw materials, wet or dry granulation, drying, tableting, coating and quality control, in one integrated solution. “For us, continuous manufacturing (CM) is fundamental to the future of the pharmaceutical industry, CM represents an exciting step forward in drug production,” said Marcus Michel, Executive Vice President of GEA’s Pharma business.

By using this system, Vertex Pharmaceuticals became the first pharma company to receive FDA approval for a therapeutic that was both developed and commercially manufactured using a CM platform. GEA’s ConsiGma 25 unit forms the basis of a collaboration between Pfizer, GSK and G-CON to develop the next generation of portable, continuous, miniature and modular (PCMM) solutions for pharma production. These on-demand mini-factories can be set up to manufacture medicines at any production scale, anywhere in the world where basic facilities are available.

(ID:44307685)